Theravance Biopharma Inc. (TBPH)
Theravance Bio (TBPH) Soars 8.3%: Is Further Upside Left in the Stock?
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
TBPH beats third-quarter estimates for both sales and earnings. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Officer Aziz Sawaf - Chief Financial Officer Aine Miller - Head, Development Conference Call Participants Julian Harrison - BTIG Ernie Rodriguez - TD Cowen Douglas Tsao - H.C. Wainwright Operator Ladies and gentlemen, good afternoon.
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.01 per share a year ago.
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
Theravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Aine Miller - Head, Development Rhonda Farnum - Chief Business Officer Aziz Sawaf - Chief Financial Officer Conference Call Participants Douglas Tsao - H.C. Wainright David Risinger - Leerink Partners Ernie Rodriguez - TD Cowen Liisa Bayko - Evercore ISI Operator Ladies and gentlemen, good afternoon.
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.13 per share a year ago.
Here's Why You May Invest in Theravance (TBPH) Stock Now
Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.
Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know
The mean of analysts' price targets for Theravance Bio (TBPH) points to a 90.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
